A Study To Evaluate The Safety And Tolerability Of SB-656933-AAA Following Repeated Doses In Healthy Adult Subjects

A Randomised, Double-blind, Placebo Controlled, Dose Ascending, Parallel Group Study to Evaluate the Safety, Tolerability, Steady State Pharmacokinetics and Pharmacodynamics of SB-656933-AAA Following Repeated Doses in Healthy Adult Subjects. The Pharmacokinetic Interaction Between Repeated Doses of SB-656933-AAA and Single Dose of Simvastatin Will Also be Assessed

To assess safety of SB-656933 following repeat dosing for 14 days.

A randomised, double-blind, placebo controlled, dose ascending, parallel group study to evaluate the safety, tolerability, steady state pharmacokinetics and pharmacodynamics of SB-656933-AAA following repeated doses in healthy adult subjects. The pharmacokinetic interaction between repeated doses of SB-656933-AAA and single dose of simvastatin will also be assessed.

Inclusion Criteria:

• Healthy adult female, aged 18-65 years.
• Female must not be able to have children.
• Non-smoking for the last 6 months.

Exclusion Criteria:

• Any serious medical condition.
• Hepatitis B or C and/or HIV positive.
• Currently on HRT, or other medication except paracetamol.
• Body Mass Index >30.